Skip to content

Services
Study Designer
Resources
Insights & Case Studies
- Case Studies
- Insights

Services
Study Designer
Resources
Insights & Case Studies
- Case Studies
- Insights

Inovia Bio Insights

Keep Up To Date With All Things Inovia Bio &
Drug Development

Line chart of required sample size for a first efficacy trial climbing steeply as the assumed effect size narrows, illustrating the plausible-range 'cone'

Powering your first efficacy trial: stop defending the number, start reading the curve

Diagram comparing basket, umbrella and platform trial designs and which master-protocol design a single-asset biotech can sponsor

drug developmentMethodology

Basket, umbrella, platform: which master-protocol design a single-asset biotech can actually sponsor

Inovia Bio graphic on adaptive trial design trade-offs across group-sequential, sample-size re-estimation and seamless Phase II/III designs

Strategydrug developmentMethodology

Adaptive trial designs: which mechanism pays, and which one quietly charges you

Strategydrug development

The read-only TPP: writing a target product profile that actually drives decisions

Diagram of a five-factor indication prioritisation framework for biotech: probability of technical success, unmet need, regulatory pathway, competitive density and time to readout

Strategydrug development

Indication prioritisation in under 20 days: the scoring framework

Overlapping trial recruitment zones drawing on a shared patient pool, illustrating how registry intelligence exposes competitive saturation in clinical trial site selection.

Strategydrug development

The shared pool: reading competitive saturation off the registry before you sign a site

Wet concrete setting around a clinical trial protocol, illustrating how HEOR decisions in clinical trial design lock the day the protocol does

StrategyIEPdrug development

The four decisions with an expiry date: why HEOR belongs in the IEP before the protocol locks

Diagram of evidence generation sequencing, showing a load-bearing feasibility study feeding the pivotal trial that structurally depends on its output.

StrategyIEPdrug development

The evidence roadmap: sequencing studies by what other studies structurally need

Checklist diagram of the seven components of a target trial emulation protocol, used to win FDA and EMA regulatory confidence

RWEStrategyReal world evidenceMethodology

Target trial emulation for non-statisticians: why the protocol wins the regulator, not the maths

Inovia Bio graphic on choosing a pivotal-trial endpoint that satisfies both regulators and payers

StrategyIEPdrug development

The second invoice: choosing a pivotal-trial endpoint that clears the regulator and the payer

Previous page 1 2 3...9 Next page

Privacy Policy · © 2025. All rights reserved.